BIIB
Price
$253.40Alerts
Change
+$0.15 (+0.06%)
Updated
Nov 11 closing price
Capitalization
36.69B
98 days until earnings call
Intraday BUY SELL Signals
OGN
Price
$13.89Alerts
Change
-$0.00 (-0.00%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
3.64B
99 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BIIB vs OGN

BIIB vs OGN Comparison Chart in %
View a ticker or compare two or three
VS
BIIB vs. OGN commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and OGN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BIIB with price predictions
Nov 10, 2026

Momentum Indicator for BIIB turns positive, indicating new upward trend

BIIB saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 55 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 165 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

The Aroon Indicator entered an Uptrend today. In 122 of 197 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.

Bearish Trend Analysis

The 10-day RSI Indicator for BIIB moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 16 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 58 cases where BIIB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for BIIB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In 36 of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.947) is normal, around the industry mean (-1.421). P/E Ratio (43.724) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).

The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.

A.I.Advisor
a Summary for OGN with price predictions
Nov 10, 2026

OGN in -0.43% downward trend, falling for three consecutive days on November 05, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OGN declined for three days, in 241 of 323 cases, the price declined further within the following month. The odds of a continued downward trend are 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

OGN broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on OGN as a result. In 53 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for OGN just turned positive on October 29, 2026. Looking at past instances where OGN's MACD turned positive, the stock continued to rise in 22 of 35 cases over the following month. The odds of a continued upward trend are 63%.

Following a +0.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where OGN advanced for three days, in 180 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

The Aroon Indicator entered an Uptrend today. In 90 of 235 cases where OGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 38%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 40 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating fairly steady price growth. OGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.621) is normal, around the industry mean (-1.421). P/E Ratio (17.557) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.738). Dividend Yield (0.006) settles around the average of (0.038) among similar stocks. OGN's P/S Ratio (0.589) is slightly lower than the industry average of (4.033).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.

FUNDAMENTALS RATINGS
BIIB: Fundamental Ratings
BIIB
OUTLOOK RATING
1..100
36
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
84
PRICE GROWTH RATING
1..100
6
P/E GROWTH RATING
1..100
3
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BIIBOGN
RSI
ODDS (%)
Bearish Trend 2 days ago
57%
Bearish Trend 2 days ago
42%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
64%
Momentum
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 2 days ago
63%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
55%
Advances
ODDS (%)
Bullish Trend 3 days ago
60%
Bullish Trend 2 days ago
63%
Declines
ODDS (%)
Bearish Trend 9 days ago
67%
Bearish Trend 7 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
65%
Aroon
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
38%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (BIIB: $253.25 vs. OGN: $13.89)
Brand notoriety: BIIB: Notable vs. OGN: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 55% vs. OGN: 100%
Market capitalization -- BIIB: $36.69B vs. OGN: $3.64B
BIIB [@Pharmaceuticals: Major] is valued at $36.69B. OGN’s [@Pharmaceuticals: Major] market capitalization is $3.64B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.21T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $215.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 2 FA rating(s) are green while OGN’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 2 green, 3 red.
  • OGN’s FA Score: 1 green, 4 red.
According to our system of comparison, OGN is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 3 TA indicator(s) are bullish while OGN’s TA Score has 4 bullish TA indicator(s).

  • BIIB’s TA Score: 3 bullish, 5 bearish.
  • OGN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, OGN is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +1.74% price change this week, while OGN (@Pharmaceuticals: Major) price change was +0.43% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.33%. For the same industry, the average monthly price growth was +2.53%, and the average quarterly price growth was +7.15%.

Reported Earning Dates

BIIB is expected to report earnings on Feb 17, 2027.

OGN is expected to report earnings on Feb 18, 2027.

Industries' Descriptions

@Pharmaceuticals: Major (-1.33% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
Interact to see
Advertisement

OGN and

Correlation & Price change

A.I.dvisor tells us that OGN and AMGN have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OGN and AMGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OGN
1D Price
Change %
OGN100%
+0.29%
AMGN - OGN
22%
Poorly correlated
N/A
BMY - OGN
22%
Poorly correlated
+1.06%
SNY - OGN
21%
Poorly correlated
+0.23%
BIIB - OGN
21%
Poorly correlated
-0.64%
GSK - OGN
21%
Poorly correlated
-0.60%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPCH8.360.12
+1.46%
Leverage Shares 2X Long SPCX Daily ETF (SPCH)
SMAY27.87-0.12
-0.43%
FT Vest U.S. Small Cap Moderate Buffer ETF - May (SMAY)
OWN23.96-0.12
-0.49%
Inside Ownership 100 ETF (OWN)
TCHP47.37-0.46
-0.96%
T. Rowe Price Blue Chip Growth ETF (TCHP)
TLTP19.42-0.22
-1.12%
Amplify TLT U.S. Treasury 12% Option Income ETF (TLTP)